NDA 207648 · Fresenius Kabi USA
Smoflipid 20%
Fish Oil, Medium Chain Triglycerides, Olive Oil, Soybean Oil · Intravenous · Lipid Emulsion
Last checked: Nov 19, 2026Latest source record: Jul 24, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2016
Jul 13, 2016
Approved uses
2
Original approval plus efficacy supplements
Registered trials
448
117 Phase 3, 14 recruiting
FAERS reports
874
665 serious, 105 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Aug 15, 2025.
SMOFlipid is indicated in adult and pediatric patients, including term and preterm neonates, as a source of calories and essential fatty acids for parenteral nutrition (PN) when oral or enteral nutrition is not possible, insufficient, or contraindicated. SMOFlipid is indicated in adult and pediatric patients, including term and preterm neonates, as a source of calories and essential fatty acids for parenteral nutrition when oral or enteral nutrition is not possible, insufficient, or contraindicated. ( 1 )
Mechanism: SMOFlipid provides a biologically utilizable source of calories and essential fatty acids. Fatty acids serve as an important substrate for energy production. The most common mechanism of action for energy production derived from fatty acid metabolism is beta oxidation. Fatty acids are also important for membrane structure and function, as precursors for bioactive molecules (such as prostaglandins), and as regulators of gene expression.
Therapeutic areas: Cardiovascular and metabolic
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Mar 22, 2022 Supplement 5 · Efficacy · priority review LabelLetter
- Jul 13, 2016 Original approval · Type 4 - New Combination LabelReviewLetter
4 products under this application
- SMOFLIPID 20% · FISH OIL 3GM/100ML; MEDIUM CHAIN TRIGLYCERIDES 6GM/100ML; OLIVE OIL 5GM/100ML; SOYBEAN OIL 6GM/100ML (1000ML) · EMULSION, INTRAVENOUS · Prescription
- SMOFLIPID 20% · FISH OIL 3GM/100ML; MEDIUM CHAIN TRIGLYCERIDES 6GM/100ML; OLIVE OIL 5GM/100ML; SOYBEAN OIL 6GM/100ML (250ML) · EMULSION, INTRAVENOUS · Prescription
- SMOFLIPID 20% · FISH OIL 3GM/100ML; MEDIUM CHAIN TRIGLYCERIDES 6GM/100ML; OLIVE OIL 5GM/100ML; SOYBEAN OIL 6GM/100ML (500ML) · EMULSION, INTRAVENOUS · Prescription
- SMOFLIPID 20% · FISH OIL 3GM/100ML; MEDIUM CHAIN TRIGLYCERIDES 6GM/100ML; OLIVE OIL 5GM/100ML; SOYBEAN OIL 6GM/100ML (100ML) · EMULSION, INTRAVENOUS · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Fish Oil" as an intervention, any sponsor and status, largest first.
- Vitamin D and Omega-3 Hypertension Trial (VITAL Hypertension)Pivotal-lookingActive, not recruiting
Brigham and Women's HospitalAcademic, hospital or other
NCT01653678 · 25,875 participants · Start Nov 2011 · Primary completion Nov 2025
Drug: Omega-3 fatty acids (fish oil); Fish oil placebo · For: Hypertension
Sites: Boston, Massachusetts
- Dry Eye Disease in the Vitamin D and Omega-3 Trial (VITAL)Pivotal-lookingStatus unknown
Brigham and Women's HospitalAcademic, hospital or other
NCT01880463 · 25,875 participants · Start Jul 2010 · Primary completion Dec 2020
Drug: Omega-3 fatty acids (fish oil); Fish oil placebo · For: Dry Eye Disease
- Effects of Vitamin D and Omega-3 Fatty Acids on Infectious Diseases and hCAP18 (VITAL Infection)Pivotal-lookingActive, not recruiting
Brigham and Women's HospitalAcademic, hospital or other
NCT01758081 · 25,874 participants · Start Jul 2010 · Primary completion Dec 2026
Drug: omega-3 fatty acids (fish oil) · For: Infections; Human Cathelicidin Antimicrobial Peptide (hCAP-18)
Sites: Boston, Massachusetts
- VITamin D and OmegA-3 TriaL: Interrelationship of Vitamin D and Vitamin K on Bone (VITAL)Pivotal-lookingActive, not recruiting
Brigham and Women's HospitalAcademic, hospital or other
NCT04573946 · 25,871 participants · Start Jul 1, 2019 · Primary completion Jul 21, 2023
Drug: Omega-3 fatty acids (fish oil) · For: Bone Density; Bone Health; Fractures
Sites: Boston, Massachusetts
- VITamin D and OmegA-3 TriaL (VITAL): Fractures, Vitamin D and Genetic MarkersPivotal-lookingCompleted
Brigham and Women's HospitalAcademic, hospital or other
NCT01704859 · 25,871 participants · Start Jun 1, 2018 · Primary completion Mar 31, 2022
Drug: omega-3 fatty acids (fish oil) · For: Fractures
Sites: Boston, Massachusetts
- Intervention With Vitamin D and Omega-3 Supplements and Incident Heart FailurePivotal-lookingCompleted
Brigham and Women's HospitalAcademic, hospital or other
NCT02271230 · 25,871 participants · Start Aug 2014 · Primary completion Dec 2019
Drug: Vitamin D and fish oil; Vitamin D alone · For: Heart Failure
Sites: Boston, Massachusetts
- Vitamin D and Omega-3 Trial (VITAL)Pivotal-lookingActive, not recruiting
Brigham and Women's HospitalAcademic, hospital or other
NCT01169259 · 25,871 participants · Start Jul 2010 · Primary completion Nov 10, 2018
Drug: omega-3 fatty acids (fish oil) · For: Cancer; Cardiovascular Disease
Sites: Boston, Massachusetts
- Age-related Macular Degeneration (AMD) in the Vitamin D and Omega-3 Trial (VITAL)Pivotal-lookingStatus unknown
Brigham and Women's HospitalAcademic, hospital or other
NCT01782352 · 25,871 participants · Start Jul 2010 · Primary completion Dec 2019
Drug: Omega-3 fatty acids (fish oil) · For: Age-related Macular Degeneration
Sites: Boston, Massachusetts
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- pyrexia58
- vomiting53
- off label use52
- nausea51
- malaise41
- dyspnoea38
- death36
- intentional product use issue34
- chills31
- fatty acid deficiency31
- hypertriglyceridaemia31
- diarrhoea29
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2011 | 1 |
| 2012 | 2 |
| 2014 | 10 |
| 2015 | 8 |
| 2016 | 34 |
| 2017 | 78 |
| 2018 | 121 |
| 2019 | 98 |
| 2020 | 64 |
| 2021 | 68 |
| 2022 | 60 |
| 2023 | 91 |
| 2024 | 93 |
| 2025 | 75 |
| 2026 | 71 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- A systematic review and meta-analysis of fish oil encapsulation within different micro/nanocarriers.
Khoshnoudi-Nia S, Forghani Z, Jafari SM · Crit Rev Food Sci Nutr 2022 · Meta-Analysis, Systematic Review
- The impact of fish oil and/or probiotics on serum fatty acids and the interaction with low-grade inflammation in pregnant women with overweight and obesity: secondary analysis of a randomised controlled trial.
Houttu N, Vahlberg T, Miles EA, et al. · Br J Nutr 2024 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- A Mediterranean-style dietary intervention supplemented with fish oil improves diet quality and mental health in people with depression: A randomized controlled trial (HELFIMED).
Parletta N, Zarnowiecki D, Cho J, et al. · Nutr Neurosci 2019 · Randomized Controlled Trial
- Fish oil supplementation and insulin sensitivity: a systematic review and meta-analysis.
Gao H, Geng T, Huang T, et al. · Lipids Health Dis 2017 · Meta-Analysis, Systematic Review
- Omega-3 fatty acids in parenteral nutrition - A systematic review with network meta-analysis on clinical outcomes.
Pradelli L, Mayer K, Klek S, et al. · Clin Nutr 2023 · Systematic Review, Research Support, Non-U.S. Gov't
- Nutritional interventions in patients with burn injury: an umbrella review of systematic reviews and meta-analyses of randomised clinical trials.
Naeini F, Zeraattalab-Motlagh S, Rahimlou M, et al. · Br J Nutr 2024 · Systematic Review, Meta-Analysis
Sponsor: Fresenius Kabi USA
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.